AstraZeneca India Q2 FY27 Revenue Jumps 30% to ₹729 Crore; Gets 3 New Approvals
AstraZeneca Pharma India reported a 30% growth in Q2 FY27, with total revenue reaching ₹7,291 million (₹729.1 crore). The company secured three new regulatory approvals, including for Trastuzumab deruxtecan and Acalabrutinib. Strategic initiatives include MoUs with Andhra Pradesh and Telangana for oncology and lung cancer screening.
The substantial revenue growth, multiple new drug approvals, and strategic partnerships with state governments indicate a significant positive impact on the company's market position, future revenue streams, and patient reach in India.
The company reported strong financial growth (30%), secured multiple new regulatory approvals for key drugs, and launched significant strategic initiatives aimed at improving patient care and disease management. These factors indicate positive performance and future outlook.
AstraZeneca Pharma India Limited announced its financial results for the second quarter and half year ended September 30, 2026, reporting a significant growth of 30% for Q2 FY27. The company's total revenue from operations reached ₹7,291 million (₹729.1 crore) in Q2 FY27, contributing to a total revenue of ₹14,119 million (₹1,411.9 crore) for the first half of FY27, also a 30% increase from the previous year.
This strong performance was driven by consistent growth across its key therapy areas: Oncology, Biopharmaceuticals, and Rare Disease. The company attributed this success to disciplined execution, operational efficiency, portfolio expansion, and the increasing adoption of innovative therapies addressing unmet patient needs in India.
In addition to financial achievements, AstraZeneca India secured three new regulatory approvals during Q2, reinforcing its leadership. These include multiple approvals for Trastuzumab deruxtecan for various stages and types of breast cancer, an approval for Benralizumab for hypereosinophilic syndrome, and two approvals for Acalabrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma.
The company also highlighted several strategic initiatives. These include a Memorandum of Understanding (MoU) with the Government of Andhra Pradesh to develop a 360-degree Oncology Care Model and establish an Integrated Genomic Solutions Centre. Another MoU was signed with the Government of Telangana to introduce AI-enabled lung cancer screening across public healthcare facilities. Furthermore, AstraZeneca launched 'K+ Connect' to improve hyperkalaemia management in heart failure and chronic kidney disease, and 'India Coronary Conquest 2026' to advance cardiovascular care.
AstraZeneca Pharma India also received recognition, including the Medical Excellence Award for Rare Disease contributions and a Runner-up position in Marketing Excellence at the OPPI India Awards 2026. The company was also awarded a Gold Award at the ETHRWorld Employee Experience Awards 2026 for Exceptional Employee Experience.
What to do with a filing like this
AstraZeneca Pharma India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by AstraZeneca Pharma India Limited. Read the original for the full detail.